Conditions: Multiple Myeloma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 16
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the safety and tolerability of dasatinib with bortezomib in the treatment of relapsed or refractory multiple myeloma.

Detailed description:

Arms:
arm 1: Phase I dose escalation study

Interventions: intervention 1: Dasatinib intervention 2: Bortezomib intervention 3: Dexamethasone
Intervention descriptions: intervention 1: Tablets; oral; approximately 2 years on study, depending on response; 50 mg once daily (QD), 100 mg QD, 140 mg QD intervention 2: Powder; intravenous; approximately 2 years on study, depending on response; 1.0 mg/m\^2 QD, 1.3 mg/m\^2 QD intervention 3: Tablets; oral; approximately 2 years on study, depending on response; 20 mg QD

Protocol document: